受强制性开放获取政策约束的文章 - Mark Levis了解详情
无法在其他位置公开访问的文章：5 篇
A phase II study of midostaurin and 5-azacitidine for untreated elderly and unfit patients with FLT3 wild-type acute myelogenous leukemia
BK Tomlinson, MM Gallogly, DM Kane, L Metheny, HM Lazarus, ...
Clinical Lymphoma Myeloma and Leukemia 20 (4), 226-233. e1, 2020
强制性开放获取政策： US National Institutes of Health
Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis
S Kayser, MJ Levis, RF Schlenk
Expert review of clinical pharmacology 10 (11), 1177-1189, 2017
强制性开放获取政策： US National Institutes of Health
Lestaurtinib: a multi-targeted FLT3 inhibitor
AT Fathi, M Levis
Expert review of hematology 2 (1), 17-26, 2009
强制性开放获取政策： US National Institutes of Health
Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study
CM Durand, AA Capoferri, AD Redd, M Zahurak, DIS Rosenbloom, ...
The Lancet HIV 7 (9), e602-e610, 2020
强制性开放获取政策： US National Institutes of Health
Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia
MW Evans, AD Sung, I Gojo, M Tidwell, J Greer, M Levis, J Karp, MR Baer
Leukemia & Lymphoma 53 (4), 660-664, 2012
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：131 篇
Targeting FLT3 mutations in AML: review of current knowledge and evidence
N Daver, RF Schlenk, NH Russell, MJ Levis
Leukemia 33 (2), 299-312, 2019
强制性开放获取政策： Cancer Research UK
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
CC Smith, Q Wang, CS Chin, S Salerno, LE Damon, MJ Levis, AE Perl, ...
Nature 485 (7397), 260-263, 2012
强制性开放获取政策： US National Institutes of Health, Doris Duke Charitable Foundation
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
PP Zarrinkar, RN Gunawardane, MD Cramer, MF Gardner, D Brigham, ...
Blood, The Journal of the American Society of Hematology 114 (14), 2984-2992, 2009
强制性开放获取政策： US National Institutes of Health
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Z Zeng, Y Xi Shi, IJ Samudio, RY Wang, X Ling, O Frolova, M Levis, ...
Blood, The Journal of the American Society of Hematology 113 (24), 6215-6224, 2009
强制性开放获取政策： US National Institutes of Health
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
AE Perl, JK Altman, J Cortes, C Smith, M Litzow, MR Baer, D Claxton, ...
The Lancet Oncology 18 (8), 1061-1075, 2017
强制性开放获取政策： US National Institutes of Health
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
F Ravandi, JE Cortes, D Jones, S Faderl, G Garcia-Manero, ...
Journal of clinical oncology 28 (11), 1856-1862, 2010
强制性开放获取政策： US National Institutes of Health
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
M Levis, F Ravandi, ES Wang, MR Baer, A Perl, S Coutre, H Erba, ...
Blood, The Journal of the American Society of Hematology 117 (12), 3294-3301, 2011
强制性开放获取政策： US National Institutes of Health
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
F Ravandi, ML Alattar, MR Grunwald, MA Rudek, T Rajkhowa, MA Richie, ...
Blood, The Journal of the American Society of Hematology 121 (23), 4655-4662, 2013
强制性开放获取政策： US National Institutes of Health
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3–internal tandem …
JE Cortes, H Kantarjian, JM Foran, D Ghirdaladze, M Zodelava, ...
Journal of clinical oncology 31 (29), 3681-3687, 2013
强制性开放获取政策： US National Institutes of Health
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
M Levis
Hematology 2013, the American Society of Hematology Education Program Book …, 2013
强制性开放获取政策： US National Institutes of Health
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
SR McCurdy, JA Kanakry, MM Showel, HL Tsai, J Bolaños-Meade, ...
Blood, The Journal of the American Society of Hematology 125 (19), 3024-3031, 2015
强制性开放获取政策： US National Institutes of Health
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
T Sato, X Yang, S Knapper, P White, BD Smith, S Galkin, D Small, ...
Blood, The Journal of the American Society of Hematology 117 (12), 3286-3293, 2011
强制性开放获取政策： US National Institutes of Health, Cancer Research UK
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
KW Pratz, T Sato, KM Murphy, A Stine, T Rajkhowa, M Levis
Blood, The Journal of the American Society of Hematology 115 (7), 1425-1432, 2010
强制性开放获取政策： US National Institutes of Health
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
A Galanis, H Ma, T Rajkhowa, A Ramachandran, D Small, J Cortes, ...
Blood, The Journal of the American Society of Hematology 123 (1), 94-100, 2014
强制性开放获取政策： US National Institutes of Health
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
J Cortes, AE Perl, H Döhner, H Kantarjian, G Martinelli, T Kovacsovics, ...
The Lancet Oncology 19 (7), 889-903, 2018
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定